BRISTOL-MYERS SQUIBB CO (BMY:NYSE)
$59.39 0.26 (0.4397%)
Analysed BRISTOL-MYERS SQUIBB CO (BMY:NYSE) News Sources
Why Dow Jones Stock Merck Skidded 4% — And Boosted A Key Rival
21-04-2026
yahoo.com
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
21-04-2026
yahoo.com
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
21-04-2026
yahoo.com
Geronimo Power Announces Start of Operations at Blevins Solar
21-04-2026
yahoo.com
Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
21-04-2026
yahoo.com
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others
20-04-2026
yahoo.com
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1?
20-04-2026
yahoo.com
BMY Stock: Analysts See 16% Upside and a Strong Buy
20-04-2026
247wallst.com
TD Cowen Initiates on MapLight (MPLT); Says It’s Undervalued on Schizophrenia Alone
20-04-2026
yahoo.com
Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term
20-04-2026
yahoo.com
What is the current price of BRISTOL-MYERS SQUIBB CO (BMY:NYSE)?
The current price of BRISTOL-MYERS SQUIBB CO (BMY:NYSE) is $59.39.
BRISTOL-MYERS SQUIBB CO (BMY:NYSE) absolute price change since previous trading day?
The absolute price change of BRISTOL-MYERS SQUIBB CO (BMY:NYSE) since the previous trading day is $0.26.
BRISTOL-MYERS SQUIBB CO (BMY:NYSE) percentage price change since previous trading day?
The percentage price change of BRISTOL-MYERS SQUIBB CO (BMY:NYSE) since the previous trading day is 0.4397%.
What is the most recent average sentiment score for BRISTOL-MYERS SQUIBB CO (BMY:NYSE)?
The most recent average sentiment score for BRISTOL-MYERS SQUIBB CO (BMY:NYSE) is 70 out of 100.
What is the most recent average sentiment for BRISTOL-MYERS SQUIBB CO (BMY:NYSE)?
The most recent sentiment for BRISTOL-MYERS SQUIBB CO (BMY:NYSE) is .
SEC-8K** Filing Available For BRISTOL-MYERS SQUIBB CO (BMY:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.